Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 + indacaterol versus indacaterol in moderate to severe COPD
2011-005673-23Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of glycopyrronium, indacaterol in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Feb 2012; status: completed.
02
Drugs
glycopyrroniumindacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-005673-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005673-23.